AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05654506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 1800 mg subcutaneous (SC) injection (total amount 15 mL) into the right/left abdominal area once weekly for 8 doses followed by once every 2 weeks for an additional 8 doses
Study NCT04985799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neomedic KIM (Knotless Incontinence Mesh)
Description: Participants will have placement of retropubic Neomedic KIM (Knotless Incontinence Mesh) sling
Study NCT06072482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Administered orally.
Study NCT06072482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT06072482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT06072482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
Study NCT06072482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: All participants will receive SoC background immunosuppressive therapy for induction and maintenance, at the discretion of the Investigator and as supported by current guidelines, product labels and local practices and informed by the individual participant's clinical condition, preferences, and values.
Study NCT06579677 — intervention group
Intervention type: OTHER
Intervention: Without any intervention
Description: No interventions will be performed.
Study NCT06405022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Endurance Training
Description: Six week period with three weekly blocks with a 20 min brain endurance training program following a regular HIT session. Before the HIT session questionnaires are completed to measure the motivation for the HIT session and the current state of mood. In between the HIT session and the RCA session, questionnaires are completed to measure the experienced workload of the HIT session, the current state of mood, and the motivation for following the RCA session. Immediately after the RCA session, questionnaires are completed to measure the experienced workload of the RCA session and the current state of mood.
Study NCT06494280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: programmed intermittent Bolus epidural analgesia
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the study group protocol for pain maintenance, i.e., a programmed intermittent bolus of 10 ml of 0.1% bupivacaine and 2 μg/ml fentanyl every hour until the completion of labor and suturing of the incision. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score >30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study NCT06494280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural infusion
Description: About 30 minutes after the end of the epidural and administration of the loading dose, the woman will be asked to report her pain level. If the VAS score \<30, the woman will receive the control group protocol for pain maintenance, i.e., 0.1% Bupivacaine and 2 μg/ml fentanyl as a continuous infusion per one hour, until the delivery is completed, and laceration is sutured. The participant can add to herself 5 ml of the same solution of Bupivacaine and Fentanyl every 30 minutes. The maximum dose that the parturient is allowed to receive is 20 ml for one hour.~If a breakthrough pain appears during labor, a bolus of 10 ml of anesthetic solution with the same concentration will be added.~Participants with a VAS score >30 after 30 minutes of the loading dose will be asked to perform a new epidural (if it was decided that the epidural failed) otherwise her data will not be collected for the final analysis of the study.
Study NCT06405022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention
Study NCT05304910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered per schedule specified in the arm description.
Study NCT05304910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
Study NCT00835887 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low and high dose flavanoids
Description: treatment with flavanoid-rich or flavanoid-low cacao twice daily
Study NCT06223698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg daily
Study NCT06223698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg daily
Study NCT04949880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurovascular Drug-Eluting Balloon Dilatation Catheter
Description: The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.
Study NCT06223698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole 1 mg daily
Study NCT06223698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole 1 mg daily
Study NCT06223698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg daily
Study NCT04987541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study NCT06223698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25 mg daily
Study NCT04987541 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: intermittent theta burst stimulation
Description: stimulatory protocol
Study NCT05078333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needle
Description: dry needling (on 3 trigger points on the bilateral trapezius muscle) will applied to the other 36 randomly selected patients with an acupuncture needle with a size of 0.25x0.25 by the PMR specialist for a total of 6 sessions twice a week for 3 weeks.
Study NCT06223698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen 20 mg daily
Study NCT05078333 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high intensity laser therapy
Description: High intensity laser therapy (HILT), one of the physical therapy methods, was approved by the FDA in 2002. Its beneficial and versatile effect has been proven in the treatment of many musculoskeletal diseases. In addition to the exercise program, randomly selected 36 case patients + HILT (BTL brand 6000 series, United Kingdom), to the cervical area, for the a period of 3 week-weekdays, 15-minute period and 15 sessions (1.02 minutes for each 25 cm² painful area, analgesic phase, with an anergy 8.0 W, a dose 5 J / cm², a frequency of 25 Hz and total 125 joules) will be applied.
Study NCT06422351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP-L301
Description: Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKLR (Pyruvate Kinase L/R) gene
Study NCT05688579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid Receptor Antagonists(MRAs)
Description: Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
Study NCT05688579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blank control
Description: Participants will be treated with the original antihypertensive drugs for 48 months.
Study NCT05250271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 15 g dextrose
Description: 15 g dextrose tablets
Study NCT05955339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NOTES
Description: The intervention will include: (1) a brief training on using the patient portal to access written visit information with assistance in setting up patient portal accounts where necessary (including strategies to share notes with a caregiver), (2) post-visit reminders to use the patient portal to access written visit information.
Study NCT06223698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20 mg daily
Study NCT05972525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making supported by an in-consultation PtDA to patients with severe osteoarthritis in their hip or knee
Description: The intervention group has been involved in the development process of the PtDA. After receiving a training course in SDM and the use of a PtDA, the surgeons will practice SDM supported by an in-consultation PtDA during the consultations with the participant.
Study NCT05250271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 5 g dextrose
Description: 5 g dextrose tablets
Study NCT05250271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Protein bar
Description: 5 g carbohydrates + 10 g protein
Study NCT05955339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AUDIO
Description: The intervention will include: (1) audio recording all visits with the study clinician for six months, (2) training on how to record visits and access visit recordings, and (3) post-visit reminders listen to the visit recordings.
Study NCT06227949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris
Description: Patients will self-administer a subcutaneous injection of Luveris in addition to Gonal-F (FSH) daily until a pre-set criteria to trigger ovulation is reached.
Study NCT06279806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health application use
Description: Women will be asked to use the app for at least 8 weeks. In order to monitor the usage, the researcher will monitor whether the women log in to the Information and Counseling section from the admin panel. Women who do not log in to the Information and Counseling section will be removed from the study at this stage. A weekly reminder will be sent to women via the mobile application. The questions asked by the participants through the question-and-answer section of the mobile health application will be examined every day and answered by the researcher between 10:00-11:00 every morning and 22:00-23:00 every evening. Likewise, the content shared by women in the forum section of the mobile application will be checked daily by the researcher and content that is harmful to women will be removed.
Study NCT06279806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information of the breast cancer survivor period booklet
Description: Women in the control group will be given information of the breast cancer survivor period booklet.
Study NCT04940871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir HU 200 mg hard capsules
Description: Drug substance: Favipiravir Dose: 200 mg Administration: oral Formulation: capsules
Study NCT04155151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6 minute walk test
Description: A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
Study NCT03224247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse cutting
Description: Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.
Study NCT03224247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical splitting
Description: vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
Study NCT06332313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spina plane block
Description: ESP block is a method used to provide postoperative analgesia by injecting local anesthetic between the erector spinae muscle and the transverse process of the vertebra under ultrasound guidance, targeting the dorsal and ventral rami of thoracic and abdominal spinal nerves. The aim of this randomized controlled study is to observe whether there is a difference in tramadol consumption within 24 hours after surgery between patients who undergo RIRS operations at T11 level with different volumes of ESP blocks performed under ultrasound guidance before general anesthesia induction.
Study NCT05209828 — intervention group
Intervention type: DEVICE
Intervention: pfmmedical implantable vascular access ports
Description: Implantion of an implantable vascular access port which facilitates repeated vascular access intended for the delivery of medications, intravenous fluids, parenteral nutrition solutions or blood products and blood sampling using a Huber needle.
Study NCT04658212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D LCBDE
Description: three-dimensional (3D) video system for LCBDE (laparoscopic cholecystectomy and laparoscopic common bile duct exploration )
Study NCT04658212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography (ERCP)
Study NCT05790928 — intervention group
Intervention type: DEVICE
Intervention: Lotrafilcon A spherical contact lenses
Description: CE-marked silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia) in persons with minimal astigmatism that does not interfere with visual acuity
Study NCT04940871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HU
Description: Name: Placebo clinical sample Drug substance: placebo Dose: - Administration: oral Formulation: capsules
Study NCT05366972 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonographic measurements
Description: Posterior layers of the thoracolumbar fascia ,middle layers of the thoracolumbar fascia thickness and Lumbar interfacial triangle thickness~CSA (cross-sectional area) measurements of erector spinae muscles, quadratus lumborum muscles and the latissimus dorsi muscles
Study NCT05022251 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar discectomy
Description: surgically removing a hernia
Study NCT05734196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INZ-701
Description: Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
Study NCT05482061 — intervention group
Intervention type: OTHER
Intervention: visual analog scale (VAS).
Description: The basic tool for pain intensity research was the VAS: 1) before and after anesthesia - at the stage of the medical and nursing brigade, military mobile hospital, military medical clinical center; 2) at the stage of the medical and nursing team - within 2 days; 3) at the stage of the military mobile hospital - within 5 days; 4) at the stage of the military medical clinical center - within 7 days, at the time of discharge from the hospital; 5) at the rehabilitation stage. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the diagnostic DN4: military mobile hospital, a military medical clinical center, then at the time of discharge from a military medical clinical center. Study of the presence of an acute stress reaction - anamnesis + The Hospital Anxiety and Depression Scale. Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
Study NCT05774717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 1 gram IV (intravenous) tranexamic acid administered in the operating room just prior to starting the case (10 minutes), at time that routine preoperative antibiotic is given.
Study NCT04773899 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Procedure : Multimodal microvascular assessment at study inclusion
Description: * Vascular occlusion test (VOT) performed on the arm. Measurement of the quality of tissue reperfusion by NIRS on the thenar eminence and the digital perfusion index.~* Microcirculation reactivity is measured for each patient with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of microvascular reactivity: Acetylcholine and Nitroprusside Iontophoresis.~* Morphological analysis of the microcirculation by sublingual videomicroscopy.
Study NCT05155111 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Telemedicine consult
Description: A joint assessment between Neonatologist at bedside and Neurologist by telemedicine will be performed to assess severity of neonatal encephalopathy
Study NCT05329493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling digit device application
Description: Cooling digit device will be applied on subject's right hand ( fifth finger).
Study NCT05001945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLS-101 (Part I)
Description: MLS-101 tablet(s) by mouth once or twice daily.
Study NCT04696029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine
Description: DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C).
Study NCT05761756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Deprivation
Description: 24 hours sleep deprivation
Study NCT05761756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Oral administration of caffeine
Study NCT05761756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Oral administration of methylphenidate
Study NCT05761756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide
Description: Oral administration of sodium bicarbonate to simulate carbon dioxide exposure
Study NCT05001945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part I)
Description: Placebo tablet(s) by mouth once or twice daily.
Study NCT05001945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part II)
Description: Placebo tablet(s) by mouth once daily.
Study NCT05001945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLS-101 (Part II)
Description: MLS-101 tablet(s) by mouth once daily.
Study NCT06072105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine visits
Description: Monthly telemedicine neurological, psychological and neurorehabilitation (physio-, occupational and speech therapy) consultations
Study NCT06072105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidisciplinary, personalized symptomatic treatment
Description: Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
Study NCT06072105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary, personalized symptomatic treatment
Description: Multidisciplinary, personalized symptomatic treatment plus mobile palliative care interventions (if wished and needed)
Study NCT05469802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Inactivated Zika Virus Vaccine (PIZV)
Description: PIZV vaccine with aluminium hydroxide adjuvant IM injection.
Study NCT05469802 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline (0.9% NaCl) IM injection.
Study NCT05437991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Independent morphological quantifications by echo-doppler using ECST method
Description: The physician who is usually in charge of patient follow-up performs a first evaluation of carotid stenosis percentage by echo-doppler using ECST method. Then a second physician immediately performs a second evaluation using the same echo-doppler device without knowing first evaluation conclusions.
Study NCT06456840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ULTRASOUND
Description: Measurements will be made in musculoskeletal system ultrasonography by an international Medicine and Rehabilitation assistant physician using images obtained with the Sonosite M-Turbo device using the ImageJ program. During the measurements, the patient and the patient will be face to face and the device will be placed postero-laterally. Five standard window spacings will be used for the shoulder attachment. These are: anterior transverse, anterior longitudinal, lateral longitudinal, lateral transverse, posterior transverse.